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Introduction: Antimicrobial resistance is increasing 
rapidly in countries with low hygiene levels and poorly 
controlled antimicrobial use. The spread of resist-
ant bacteria poses a threat to healthcare worldwide. 
Refugees and migrants from high-prevalence coun-
tries may add to a rise in multidrug-resistant (MDR) 
bacteria in low-prevalence countries. However, respec-
tive data are scarce. Methods: We retrospectively col-
lected microbiological and clinical data from asylum 
seekers and refugees treated at Helsinki University 
Hospital between January 2010 and August 2017. 
Results: Of 447 asylum seekers and refugees (Iraq: 
46.5%; Afghanistan: 10.3%; Syria: 9.6%, Somalia: 
6.9%); 45.0% were colonised by MDR bacteria: 32.9% 
had extended-spectrum beta-lactamase-producing 
Enterobacteriaceae (ESBL-PE), 21.3% meticillin-resist-
ant Staphylococcus aureus (MRSA), 0.7% carbap-
enemase-producing Enterobacteriaceae (CPE), 0.4% 
multiresistant Pseudomonas aeruginosa (MRPA), 0.4% 
multiresistant Acinetobacter baumannii (MRAB); no 
vancomycin-resistant Enterococcus (VRE) were found. 
Two or more MDR bacteria strains were recorded for 
12.5% of patients. Multivariable analysis revealed 
geographical region and prior surgery outside Nordic 
countries as risk factors of MRSA colonisation. Young 
age (< 6 years old), short time from arrival to first sam-
ple, and prior hospitalisation outside Nordic countries 
were risk factors of ESBL-PE colonisation. Conclusion: 
We found MDR bacterial colonisation to be common 
among asylum seekers and refugees arriving from 
current conflict zones. In particular we found a high 
prevalence of MRSA. Refugees and migrants should, 
therefore, be included among risk populations requir-
ing MDR screening and infection control measures at 
hospitals.
Introduction
Antimicrobial resistance (AMR), a major health prob-
lem worldwide, surges most rapidly in regions with low 
level of hygiene and poor control of antimicrobial use 
[1]. AMR spreads across the globe and its extent has 
been recognised by international bodies at the high-
est level: in 2016 AMR was addressed at a General 
Assembly session of the United Nations as the greatest 
and most urgent global health risk [2].
A major concern about AMR is its spread to healthcare 
settings in low-prevalence countries with severe con-
sequences: treatment failures, increase in the number 
of serious infections, and dramatic cost implications 
[3]. To prevent the spread of AMR to hospitals, patients 
with particular risk of colonisation and infection with 
multidrug-resistant (MDR) bacteria should be identi-
fied and subjected to infection control measures at the 
admission stage. Numerous studies have identified 
international travel as a major risk factor for colonisa-
tion: approximately one third of visitors to high-prev-
alence regions acquire MDR bacteria during ordinary 
tourist travel [4-18]. Refugees and migrants who have 
lived for years in high-risk regions are presumed to 
have even higher levels of colonisation.
The European migrant crisis began in 2015 when over 1.2 
million first-time asylum seekers (this group includes 
both refugees and migrants) applied for international 
protection in European Union countries [19,20]. Finland 
received 32,476 applications for asylum in 2015, an 
almost 10-fold increase on previous years [21].
Like international travel, migration may contribute sub-
stantially to the spread of AMR [22-26]. Refugees and 
migrants mostly come from countries with consider-
ably higher rates of MDR bacteria than Finland and, 
moreover, they may have journeyed through other 
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high-prevalence regions [1]. Accurate data on colonisa-
tion rates in this population are required to estimate 
transmission risk and to prepare infection control 
guidelines for hospitals. This retrospective study inves-
tigates the prevalence of various MDR bacteria among 
asylum seekers and refugees hospitalised in Finland, 
and seeks risk factors that can be used to identify 
those at highest risk of colonisation.
Methods
Selection of participants
Helsinki University Hospital (HUCH) provides second-
ary and tertiary care for the 1.6 million inhabitants of 
southern Finland. During the study period, from January 
2010 to August 2017, our hospital’s infection control 
guidelines stated that all asylum seekers and refugees 
admitted to hospitals should be screened at entry for 
meticillin-resistant  Staphylococcus aureus  (MRSA), 
vancomycin-resistant  Enterococcus  (VRE), 
extended-spectrum beta-lactamase-producing 
Enterobacteriaceae (ESBL-PE), carbapene-
mase-producing Enterobacteriaceae (CPE), 
multiresistant  Acinetobacter baumannii  (MRAB) and 
multiresistant  Pseudomonas aeruginosa  (MRPA). The 
same screening guidelines were applied to patients 
who had been hospitalised outside the Nordic coun-
tries during the previous 12 months before admission 
to our hospital.
Using the HUCH infectious diseases database, SAI, we 
compiled a list of patients who had been sampled for 
both MRSA and multiresistant Gram-negative (MRGN) 
bacteria at hospital admission. Among these, we 
selected those with a non-Finnish/non-Swedish name 
and, after screening their patient charts, included only 
those who were asylum seekers or refugees (Figure 1). 
According to the Finnish Medical Research Act, review 
by an ethics committee is only required for research 
involving an intervention. The study protocol was 
approved by the research board of the Inflammation 
Center, Helsinki University Hospital, Finland.
Collection of patient data
For background information, we collected data from 
the patient records on sex, age, country of origin, date 
of arrival in Finland, prior hospitalisation and surgery 
(as recorded by the clinician), and determined Charlson 
Comorbidity Index (CCI) [27] for each subject. In addi-
tion, we collected data covering the results of bacte-
rial cultures (blood, urine, stool), reason for admission, 
clinical diagnosis (ICD-10) [28] at discharge, MDR bac-
terial infections identified, and deaths. For further 
analysis, patients were grouped by geographical region 
according to their country of origin. Here we applied a 
classification (Figure 2) modified from United Nations 
geoscheme (Europe, North Africa and Middle East, 
sub-Saharan Africa, Asia, other) [29].
Microbiological methods
According to the hospital guidelines, swabs for screen-
ing patients for MDR bacteria are collected as follows: 
MRSA samples are taken each with a separate swab 
from the nostrils (one swab for both), pharynx and 
rectum or perineum. MRGN bacteria samples are col-
lected as rectal swabs. In addition, swabs are taken 
from wound infections when applicable. The screening 
comprises two sets of samples, and where possible the 
samples are to be collected on consecutive days.
While some minor modifications to the routine labora-
tory practices took place during the study period, at 
the time of the last sampling, MDR bacterial analyses 
were carried out as follows: MRSA was screened by 
overnight enrichment on eMRSA broth (Copan Italia, 
Brescia, Italy) or selective in-house MRSA enrichment 
broth [30] followed by culture on CHROMagar MRSA 
(CHROMagar, Paris, France), and confirmed with  S. 
aureus-specific nuclease and mecA gene qPCR [30]. 
VRE were screened by enrichment Enterococcosel 
Broth (BBL, Cockeysville, MD, United States of America 
(USA)) and followed by culture on CHROMagar VRE 
media. Positive findings were confirmed by in-house 
PCR as described by Suppola et al. [31].
Figure 1
Flowchart showing multidrug-resistant bacteria found in 
samples from asylum seekers and refugees admitted to 
Helsinki University Hospital, Finland, January 2010 to 
August 2017 (n = 447)
Patients tested for both
MRSA and MRGN 
n =  6,423



























Origin of family name:
non-Finnish/non-Swedish
n = 2,319
CPE: carbapenemase-producing Enterobacteriaceae; ESBL-PE: 
extended-spectrum beta-lactamase-producing Enterobacteriaceae; 
MRAB: multiresistant Acinetobacter baumannii; MRGN: 
multiresistant Gram-negative bacteria; MRPA: multiresistant 
Pseudomonas aeruginosa; MRSA: meticillin-resistant 
Staphylococcus aureus; VRE: vancomycin-resistant Enterococcus.
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Figure 2
Rate of multidrug-resistant bacteria among asylum seekers and refugees admitted to Helsinki University Hospital, by 






































41–60 %  
 
Percentage of MDR carriers 
by country/region of origin 
ESBL-PE: extended-spectrum beta-lactamase-producing Enterobacteriaceae; MDR: multidrug-resistant bacteria; MRSA: meticillin-resistant 
Staphylococcus aureus.
For nine patients, country of origin was not known. One patient was from Mexico (not shown in the map).
Patients’ countries of origin in the various geographical regions:
Europe: Albania, Georgia, Greece, Kosovo*, Russia, Serbia, Ukraine;
North Africa and the Middle East: Iraq, Iran, Jordan, Kuwait, Lebanon, Morocco, Syria, Turkey, Yemen;
Sub-Saharan Africa: Burundi, Cameroon, Congo, Ethiopia, Eritrea, Gambia, Ghana, Kenya, Nigeria, Rwanda, Somalia, South Africa, Sudan, 
Uganda, Zambia;
Asia: Afghanistan, Azerbaijan, Kazakhstan, China, Kyrgyzstan, Myanmar, Nepal, Pakistan, Sri Lanka.
*This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the 
International Court of Justice Opinion on the Kosovo Declaration of Independence.
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ESBL-PE and CPE were analysed by plating directly on 
CHROMagar ESBL and CHROMagar KPC or CHROMagar 
mSuperCARBA, respectively. ESBL-PE species iden-
tification was confirmed by MALDI-TOF (Vitek-MS, 
bioMérieux, Marcy l’Étoile, France) and resistance by 
standard EUCAST method [32]. CPE species were con-
firmed with in-house carbapenemase gene PCR.
MDR-P. aeruginosa  and MDR-A. baumannii  were 
screened from ESBL and KPC SuperCARBA plates. 
Cultures were tested by MALDI-TOF for species 
identification. Isolates resistant to meropenem 
for  Acinetobacter, and both meropenem and ceftazi-
dime for  Pseudomonas, were analysed by PCR for car-
bapenemase genes as previously described [33].
Statistics
Data were entered on Microsoft Excel 2013 spread-
sheets, and statistical analyses were conducted using 
SPSS 24.0.0.0 software (IBM Corp., Armonk, NY, 
USA). In univariate analyses for categorical variables, 
chi-squared test, Fisher’s exact test or binary logistic 
regression analysis was applied. For continuous vari-
ables, we used binary logistic regression. Chi-squared 
test and Fisher’s exact test were two-sided. Variables 
for the multivariable model were selected using the 
p value limit of 0.2 in the univariate model. Time 
between arrival and first sample was not known for all 
cases; missing values were taken into account by mul-
tiple imputations, assuming that data were missing at 
random. In the multivariable model, we used backward 
selection with Akaike information criteria (AIC) so as 
to choose the most informative explanatory variables 
for the final model. From several highly correlated vari-
ables, only one was included.
Table 1
Background characteristics of asylum seekers and refugees admitted to Helsinki University Hospital, by geographical region 























n % n % n % n % n % n %
Sex
Male 8 30.8 135 50.4 32 37.2 31 54.4 4 40.0 210 47.0
Female 18 69.2 133 49.6 54 62.8 26 45.6 6 60.0 237 53.0
Median age (years) 24 26 27 20 27 25
Age group (years)
0–5 3 11.5 36 13.4 7 8.1 6 10.5 2 20.0 54 12.1
6–15 3 11.5 32 11.9 3 3.5 15 26.3 0 0.0 53 11.9
16–25 9 34.6 64 23.9 31 36.0 14 24.6 3 30.0 121 27.1
26–35 8 30.8 98 36.6 30 34.9 12 21.1 4 40.0 152 34.0
> 35 3 11.5 38 14.2 15 17.4 10 17.5 1 10.0 67 15.0
Charlson Comorbidity Index
0 points 24 92.3 251 93.7 80 93.0 52 91.2 10 100.0 417 93.3
1 point 0 0.0 3 1.1 1 1.2 2 3.5 0 0.0 6 1.3
2–3 points 2 7.7 11 4.1 4 4.7 3 5.3 0 0.0 20 4.5
4–5 points 0 0.0 1 0.4 1 1.2 0 0.0 0 0.0 2 0.4
> 5 points 0 0.0 2 0.7 0 0.0 0 0.0 0 0.0 2 0.4
Mean time from arrival to Finland 
to first sample (days) 78 127 100 119 363 119
Prior treatment history
Prior hospitalisation abroad 5 19.2 54 20.1 15 17.4 6 10.5 0 0.0 80 17.9
Prior invasive procedure abroad 2 7.7 34 12.7 9 10.5 4 7.0 0 0.0 49 11.0
aPatients’ countries of origin in the various geographical regions:
Europe: Albania, Georgia, Greece, Kosovo*, Russia, Serbia, Ukraine;
North Africa and Middle East: Iraq, Iran, Jordan, Kuwait, Lebanon, Morocco, Syria, Turkey, Yemen;
Sub-Saharan Africa: Burundi, Cameroon, Congo, Ethiopia, Eritrea, Gambia, Ghana, Kenya, Nigeria, Rwanda, Somalia, South Africa, Sudan, 
Uganda, Zambia;
Asia: Afghanistan, Azerbaijan, Kazakhstan, China, Kyrgyzstan, Myanmar, Nepal, Pakistan, Sri Lanka;
Other or unknown: Mexico, unknown.
*This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the 




According to the HUCH infectious diseases database 
SAI, 6,423 patients were screened for both MRSA and 
MRGN bacteria at admission between 1 January 2010 
and 23 August 2017. A total of 2,319 patients with a 
non-Finnish/non-Swedish name were selected and 
their patient records screened (Figure 1). The final study 
population included 447 patients with refugee or asy-
lum seeker status stated in their patient records. The 
increase in the number of refugees and asylum seekers 
admitted during the study period was evident: the vast 
majority (86.8%) were hospitalised after the beginning 
of 2015. As shown by the demographic data presented 
in Tables 1 and 2, their median age was 25 years, and 
53.0% were female. The patients had 41 different coun-
tries of origin, the majority in Iraq (46.5%), Afghanistan 
(10.3%), Syria (9.6%), and Somalia (6.9%). Most of the 
subjects (93.3%) were healthy, with a CCI-score of 0. 
Prior hospitalisation outside the Nordic countries was 
recorded for 17.9%, an invasive procedure for 11.0%, 
and treatment in an intensive care unit abroad for 4.0% 
of the patients. The median time from arrival in Finland 
to first MDR bacterial sampling was 59 days. The date 
of arrival in Finland was available for 283/447 patients 
(63.3%).
Cause of hospitalisation
An infectious disease was the primary diagnosis for 
83/447 patients (18.6%), most commonly confined 
to the respiratory (21.7%; 18/83) or urogenital tract 
(13.3%; 11/83), or presented as dermatological infection 
(16.9%; 14/83) or acute gastroenteritis (7.2%; 6/83). 
The majority of patients (81.4%) had a non-infectious 
disease and nearly one third (29.8%; 133/447) of the 
admissions were associated with pregnancy.
Findings of multidrug-resistant bacteria
Almost half of the patients (45.0%; 201/447) were col-
onised by MDR bacteria: 32.9% had ESBL-PE, 21.3% 
MRSA, 0.7% CPE, 0.4% MRPA and 0.4% MRAB (Table 
3). No cases with VRE were recorded. Two or more 
MDR strains were found in 12.5%. The proportion of 
MDR bacterial carriers was found greatest among the 
patients from Iraq and Syria (57.2% and 55.8% respec-
tively), followed by Afghanistan (34.8%) and Somalia 
(25.8%) (Table 4). Analysis by geographical region 
(Table 3) showed the highest MDR bacterial colonisa-
tion rates for patients from North Africa and the Middle 
East (56.0%). Patients from Asia and sub-Saharan 
Africa had MDR bacterial carriage rates of 38.6% and 
24.4%, respectively, while the result for those from 
Europe was 15.4% (Figure 2).
Infections with multidrug-resistant bacteria
Ten of the MDR bacterial carriers (5.0%; 10/201) had a 
clinical MDR bacterial infection verified by culture, with 
wound infections and urinary tract infections (UTI) as 
the most common manifestations. In six cases (60.0%; 
6/10) the agent was identified as ESBL-PE, and in four 
(40.0%; 4/10) as MRSA; 4.1% (6/147) of the ESBL-PE 
and 4.2% (4/95) of the MRSA carriers presented with 
a clinical infection. Among patients with a clinical 
Table 2
Background characteristics of asylum seekers and refugees admitted to Helsinki University Hospital, by country of origina, 























n % n % n % n % n % n % n %
Sex
Male 109 52.4 25 54.3 19 44.2 11 35.5 4 25.0 42 40.8 210 47.0
Female 99 47.6 21 45.7 24 55.8 20 64.5 12 75.0 61 59.2 237 53.0
Median age (years) 26 19 25 22 30 26 25
Age group (years)
0–5 27 13.0 4 8.7 5 11.6 1 3.2 1 6.3 16 15.5 54 12.1
6–15 20 9.6 12 26.1 9 20.9 2 6.5 0 0.0 10 9.7 53 11.9
16–25 54 26.0 13 28.3 9 20.9 17 54.8 4 25.0 24 23.3 121 27.1
26–35 76 36.5 10 21.7 15 34.9 8 25.8 10 62.5 33 32.0 152 34.0
> 35 31 14.9 7 15.2 5 11.6 3 9.7 1 6.3 20 19.4 67 15.0
Charlson Comorbidity Index
0 points 197 94.7 43 93.5 38 88.4 28 90.3 16 100.0 95 92.2 417 93.3
1 point 1 0.5 2 4.3 1 2.3 1 3.2 0 0.0 1 1.0 6 1.3
2–3 points 7 3.4 1 2.2 4 9.3 2 6.5 0 0.0 6 5.8 20 4.5
4–5 points 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.0 2 0.4
> 5 points 2 1.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 0.4
aThe data are only presented for the five most common countries (in total, the study population originated in 41 different countries).
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infection as primary diagnosis, 10.8% (9/83) had an 
MDR bacterial infection.
UTIs were caused by ESBL  E. coli  (one patient) or 
ESBL Klebsiella pneumoniae (one patient). As for wound 
infections, MRSA was cultured in four cases (one with 
osteomyelitis) and ESBL  Enterobacter cloacae  in one. 
One patient with a wound infection had ESBL  Proteus 
mirabilis  detected both in bacterial culture of wound 
tissue and blood. Furthermore, there was one patient 
with a finding of ESBL Shigella, and in one case 
ESBL  E. coli  was cultured from perianal abscess. No 
deaths were directly attributed to infections with MDR 
bacteria.
Meticillin-resistant Staphylococcus aureus 
findings
The frequency of MRSA findings was 21.3% (95/447) 
(Table 3). The highest rates were seen among patients 
coming from Iraq (31.3%; 65/208) and Syria (20.9%; 
9/43), followed by those from Somalia (12.9; 4/31) and 
Afghanistan (10.9%; 5/46) (Table 4). The most com-
mon Staphylococcal protein A (spa)-types of MRSA 
isolates were t304 (24.4%), t386 (11.5%), t223 (10.3%), 
t044 (6.4%), and t127 (6.4%).  Spa-types seemed to 
differ by country of origin (Table 4). The median times 
from arrival in Finland to first sample among MRSA-
carriers and non-carriers were 97 and 51 days, respec-
tively (Table 5); the difference was not statistically 
significant.
Multiresistant Gram-negative bacteria findings
CPE strains (K. pneumoniae, E. coli, Acinetobacter bau-
mannii,  and  Proteus mirabilis) were found in the sam-
ples of two patients from Iraq and one from Syria; both 
Iraqis had multiple CPE strains. MRPA was recorded for 
two patients, one Russian, the other Iraqi. One refugee 
from Cameroon and one from Iraq were screened posi-
tive for MRAB.
One third of the patients (32.9%; 147/447) were colo-
nised by ESBL-PE, with the highest frequency seen 
among patients of North African and Middle Eastern ori-
gin (41.4%; 111/268). Nearly half of the Syrians (48.8%; 
21/43) were ESBL-PE carriers, while Iraqis and Afghans 
had carriage rates of 40.4% (84/208) and 26.1% (12/46), 
respectively (Table 4). Most ESBL-PE strains were  E. 
coli (90.2%), followed by K. pneumoniae (6.1%), Proteus 
Table 3
The number of carriers of multidrug-resistant bacteria among asylum seekers and refugees admitted to Helsinki University 






















n % n % n % n % n % n %
Any MDR bacteria 4 15.4 150 56.0 21 24.4 22 38.6 4 40.0 201 45.0
MRSA 2 7.7 75 28.0 11 12.8 5 8.8 2 20.0 95 21.3
ESBL-PE 3 11.5 111 41.4 13 15.1 18 31.6 2 20.0 147 32.9
VRE 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
MRAB 0 0.0 1 0.4 1 1.2 0 0.0 0 0.0 2 0.4
MRPA 1 3.8 1 0.4 0 0.0 0 0.0 0 0.0 2 0.4
CPE 0 0.0 3 1.1 0 0.0 0 0.0 0 0.0 3 0.7
Multiple MDR bacteria 
 
≥ 2 classes or strains of MDR 
bacteria
2 7.7 48 17.9 5 5.8 1 1.8 0 0.0 56 12.5
Clinical infection with MDR bacteria 0 0.0 8 3.0 1 1.2 1 1.8 0 0.0 10 2.2
Proportion of MDR bacteria carriers 
with clinical MDR bacterial infection 
(%)
0 5.3 4.8 4.5 0 5.0
CPE: Carbapenemase-producing Enterobacteriaceae; ESBL-PE: extended-spectrum beta-lactamase-producing Enterobacteriaceae; MDR: 
multidrug-resistant; MRAB: multiresistant Acinetobacter baumannii; MRPA: multiresistant Pseudomonas aeruginosa; MRSA: meticillin-
resistant Staphylococcus aureus; VRE: Vancomycin-resistant Enterococcus.
aPatients’ countries of origin in the various geographical regions:
Europe: Albania, Georgia, Greece, Kosovo*, Russia, Serbia, Ukraine;
North Africa and Middle East: Iraq, Iran, Jordan, Kuwait, Lebanon, Morocco, Syria, Turkey, Yemen;
Sub-Saharan Africa: Burundi, Cameroon, Congo, Ethiopia, Eritrea, Gambia, Ghana, Kenya, Nigeria, Rwanda, Somalia, South Africa, Sudan, 
Uganda, Zambia;
Asia: Afghanistan, Azerbaijan, Kazakhstan, China, Kyrgyzstan, Myanmar, Nepal, Pakistan, Sri Lanka;
Other or unknown: Mexico, unknown.
bSome patients had two or more different ESBL-PE, CPE or MRSA strains.
*This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the 
International Court of Justice Opinion on the Kosovo Declaration of Independence.
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mirabilis  (2.4%) and  Enterobacter cloacae  (0.6%). The 
median time from arrival in Finland to first sample was 
significantly shorter among ESBL-PE-carriers (38 days) 
than non-carriers (83 days) (Table 5).
Extended-spectrum beta-lactamase-producing 
Enterobacteriaceae with co-resistance to other 
antimicrobials
Co-resistance to other antibiotics proved common 
among the ESBL strains: two thirds (62.2%; 102/164) 
of the ESBL-PE isolates showed decreased sensitivity 
to co-trimoxazole and more than one third were co-
resistant to levofloxacin (40.2%; 66/164) or tobramycin 
(34.1%; 56/164). Resistance to levofloxacin was associ-
ated with co-resistance to tobramycin (OR 6.0, 95% con-
fidence intervals (CI): 3.0–12.2) but not co-trimoxazole 
(OR 1.7, 95% CI: 0.9–3.3) in univariate analysis. No sta-
tistical differences were seen in co-resistance between 
the various geographical regions.
Risk factor analysis of meticillin-
resistant Staphylococcus aureus colonisation
In multivariable analysis, geographical region and prior 
invasive procedure outside the Nordic countries were 
found to be independent risk factors of MRSA colonisa-
tion. No other risk factors were identified. (Table 6)
Risk factor analysis of extended-spectrum 
beta-lactamase-producing Enterobacteriaceae 
colonisation
We identified by univariate analysis the follow-
ing factors as predisposing to ESBL-PE: young age, 
Table 4
The number of carriers of multidrug-resistant bacteria among asylum seekers and refugees admitted to Helsinki University 
























n % n % n % n % n % n % n %
Any MDR bacteria (%) 119 57.2 16 34.8 24 55.8 8 25.8 2 12.5 32 31.1 201 45.0
MRSA 65 31.3 5 10.9 9 20.9 4 12.9 1 6.3 11 10.7 95 21.3
ESBL-PE 84 40.4 12 26.1 21 48.8 6 19.4 1 6.3 23 22.3 147 32.9
VRE 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
MRAB 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.0 2 0.4
MRPA 1 0.5 0 0.0 0 0.0 0 0.0 0 0.0 1 1.0 2 0.4
CPE 2 1.0 0 0.0 1 2.3 0 0.0 0 0.0 0 0.0 3 0.7
n % n % n % n % n % n % n %
Multiple MDR bacteria 
 
≥ 2 classes or strains of MDR 
bacteria
41 19.7 1 2.2 7 16.3 3 9.7 0 0.0 4 3.9 56 12.5
Clinical infection with MDR 
bacteria 5 2.4 1 2.2 3 7.0 1 3.2 0 0.0 0 0.0 10 2.2
Proportion of MDR bacteria 
carriers with clinical MDR 
bacterial infection (%)
4.2 6.3 12.5 12.5 0 0 5.0





























































































































CPE: carbapenemase-producing Enterobacteriaceae; ESBL-PE: extended-spectrum beta-lactamase-producing Enterobacteriaceae; MDR: 
multidrug-resistant; MRAB: Multiresistant Acinetobacter baumannii; MRPA: multiresistant Pseudomonas aeruginosa; MRSA: meticillin-
resistant Staphylococcus aureus; spa: staphylococcal protein A; VRE: vancomycin-resistant Enterococcus.
aIn total, the study population originated in 41 different countries.
bSome patients had two or more different ESBL-PE, CPE or MRSA strains.
cThe spa-types of some MRSA samples were not available.
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Table 5
The results of univariate and multivariable risk factor analyses of extended-spectrum beta-lactamase-producing 












OR (95% Cl) 
in univariate 
analysis 
p value in 
univariate 
analysis 
AOR (95% CI) 
in multivariable 
analysisa 
p value in 
multivariable 
analysis 
n n % n %
Sex
  Female 237 68 28.7 169 71.3 1.0 NA NA NA
  Male 210 79 37.6 131 62.4 1.5 (1.0–2.2) 0.045 NA NA
Age group (years) < 0.001
0–5 54 30 55.6 24 44.4 1.0 NA 1.0 NA
6–15 53 16 30.2 37 69.8 0.3 (0.2–0.8)b 0.009 0.2 (0.1–0.5)b 0.001
16–25 121 30 24.8 91 75.2 0.3 (0.1–0.5)b < 0.001 0.3 (0.2–0.7)b 0.003
26–35 152 44 28.9 108 71.1 0.3 (0.2–0.6)b < 0.001 0.4 (0.2–0.8)b 0.010
> 35 67 27 40.3 40 59.7 0.5 (0.3–1.1)b 0.096 0.5 (0.2–1.2)b 0.123
Geographical regionc < 0.001
Europe 26 3 11.5 23 88.5 1.0 NA 1.0 NA
North Africa and 
Middle East 268 111 41.4 157 58.6 5.4 (1.6–18.5)
d 0.007 7.7 (2.1–28.1)d 0.002
Sub-Saharan Africa 86 13 15.1 73 84.9 1.4 (0.4–5.2)d 0.649 1.4 (0.4–5.9)d 0.617
Asia 57 18 31.6 39 68.4 3.5 (0.9–13.3)d 0.062 5.9 (1.4–24.1)d 0.014
Other or unknown 10 2 20.0 8 80.0 1.9 (0.3–13.6)d 0.516 7.0 (0.8–64.9)d 0.086
Prior hospitalisation abroad
No or not specified 367 100 27.2 267 72.8 1.0 NA 1.0 NA
Yes 80 47 58.8 33 41.3 3.8 (2.3–6.3) < 0.001 4.1 (2.3–7.4) < 0.001
Prior invasive procedure abroad
No or not specified 398 118 29.6 280 70.4 1.0 NA NA NA
Yes 49 29 59.2 20 40.8 3.4 (1.9–6.3) < 0.001 NA NA
Prior ICU care abroad
No or not specified 429 134 31.2 295 68.8 1.0 NA NA NA
Yes 18 13 72.2 5 27.8 5.7 (2.0–16.4) 0.001 NA NA
Time from arrival to 
first sample (days, 
median)e
59 38 83 0.91 (0.85–0.96)e 0.002 0.91 (0.86–0.97) 0.002
Charlson Comorbidity Index (points) 0.063
0 417 133 31.9 284 68.1 1.0 NA NA NA
1 6 1 16.7 5 83.3 0.4 (0.05–3.7)f 0.439 NA NA
2–3 20 13 65.0 7 35.0 4.0 (1.5–10.2)f 0.004 NA NA
4–5 2 0 0 2 100 NA NA NA NA
> 5 2 0 0 2 100 NA NA NA NA
AOR: adjusted odds ratio; CI: confidence interval; ESBL-PE: extended-spectrum beta-lactamase-producing Enterobacteriaceae; ICU: intensive 
care unit; NA: not applicable; OR: odds ratio; SD: standard deviation.
aWhen selecting the variables for the multivariable model with binary logistic regression, the Akaike information criteria (AIC) was used. Time 
between arrival and first sample was not known for all cases; missing values were taken into account by multiple imputations, assuming 
that data were missing at random.
bCompared with the youngest age group.
cPatients’ countries of origin in the various geographical regions:
Europe: Albania, Georgia, Greece, Kosovo*, Russia, Serbia, Ukraine;
North Africa and Middle East: Iraq, Iran, Jordan, Kuwait, Lebanon, Morocco, Syria, Turkey, Yemen;
Sub-Saharan Africa: Burundi, Cameroon, Congo, Ethiopia, Eritrea, Gambia, Ghana, Kenya, Nigeria, Rwanda, Somalia, South Africa, Sudan, 
Uganda, Zambia;
Asia: Afghanistan, Azerbaijan, Kazakhstan, China, Kyrgyzstan, Myanmar, Nepal, Pakistan, Sri Lanka.
dCompared with Europe.
en = 283; only in 283/447 cases arrival date to Finland was known. Analysed as a continuous variable, OR and adjusted OR given per 30 days.
fCompared with those with 0 points.
*This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the 
International Court of Justice Opinion on the Kosovo Declaration of Independence.
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geographical region, short time from arrival to first 
sample, prior hospitalisation, prior invasive procedure 
abroad, and prior ICU care (Table 5). The final multi-
variable analysis revealed geographical region of ori-
gin, age under 6 years, short time from arrival to first 
sample and prior hospitalisation abroad as independ-
ent risk factors for colonisation. As for the geographi-
cal region of origin, the ESBL-PE colonisation rates 
were significantly higher among North African, Middle 
Eastern and Asian patients than Europeans (Table 5). 
Of factors with p value under 0.2 in univariate analysis, 
male sex, prior invasive procedure abroad, prior ICU 
care, and general health (CCI score) were eliminated 
from the final model on the basis of the AIC.
Discussion
Data remain scarce on AMR carriage rates in refugees 
and migrants [24]. The present investigation reveals 
MDR bacterial colonisation and a high prevalence of 
MRSA of 21.3% among asylum seekers and refugees 
seeking healthcare at a tertiary hospital in Finland.
Although focusing on AMR, we also collected general 
data on refugees and migrants and causes of their 
hospitalisation. Although 79% of the asylum seek-
ers who have arrived in Finland since 2015 have been 
male [34], in our data no clear sex difference in hos-
pital admission was seen; the discrepancy can prob-
ably be explained by our high number of obstetric 
hospitalisations. Overall, our patients were in good 
general health; the greatest number of visits (29.8%) 
were reported for the specialty of obstetrics, while 
infectious diseases accounted for fewer than one in 
five cases. Respiratory, skin, and urinary tract infec-
tions were the most common causes among infectious 
diseases. Obviously, these are also common causes of 
hospitalisation among the host population. The pro-
portion of minors corresponded to that of refugee and 
migrant minors arriving in Finland (24.9%) [35].
Level of colonisation by any multidrug-
resistant bacteria
Nearly half of the patients were colonised by MDR bac-
teria, a finding consistent with recent research focusing 
on refugees admitted to hospitals [36-38]. In Germany, 
Tenenbaum et al. reported an MDR bacterial carriage 
rate of 33.8% (110/325) in a paediatric population in 
2015 to 2016 [36], and Reinheimer et al. rates of 52.1% 
(61/117) in 2015 to 2016 and 66.4% (95/143) in 2015 
in two studies with both adult and paediatric patients 
[37,38]. The various countries of birth may account for 
the differences: in the previous studies, most of the 
patients were Syrians and Afghans, whereas in ours, 
nearly half were Iraqis. The high overall rate of MDR 
bacterial colonisation among refugees and asylum 
seekers justifies infection control measures, accord-
ing with rates of 55.2% demonstrated in another group 
routinely subjected to isolation at hospitals in low-
prevalence countries, namely travellers with a recent 
history of hospitalisation in the (sub)tropics [39].
As we expected, the clinical ESBL-PE infections gener-
ally proved to be UTIs; MDR bacterial wound infections 
were mostly attributed to MRSA. Data on the frequency 
of MDR bacterial carriers developing an infection with 
the MDR bacterial strain are scarce. Among returning 
travellers treated on an infectious and tropical dis-
eases ward in France from 2012 to 2013, Epelboin et 
al. [40] found that one in five MRGN bacterial carri-
ers identified (21.7%, 5/23) also had a clinical MRGN 
bacterial infection, albeit in a very small sample. The 
difference between our rates and those of Epelboin 
et al. (5.0% vs 21.7%, respectively) can probably be 
explained by two points related to the selection of 
population. Firstly, our data included a high propor-
tion of healthy obstetric patients with no MDR bacterial 
infections. Secondly, in the investigation by Epelboin 
all patients had a clinical infection, while ours looked 
retrospectively at all patients, admitted for any reason, 
who at admission to a tertiary hospital had been sam-
pled for both MRSA and MRGN bacteria, and whom we 
could identify as asylum seekers and refugees from 
their patient records. Indeed, of our patients who had 
infectious disease as primary diagnosis, 10.8% had 
an MDR bacterial infection. In our previous study look-
ing at 1,122 Finnish patients hospitalised abroad for 
diverse reasons, we found that 11.4% (38/333) of those 
colonised with MDR bacteria had an infection with the 
same MDR bacteria [39].
Colonisation by MRSA
A major finding emerging from our investigation was 
that MRSA carriage in asylum seekers and refugees is 
considerably more common than expected. This pro-
portion significantly exceeds those of German stud-
ies that have reported rates from 5.6% to 9.8% (8/143 
and 32/325) [37,41], and rates of 15.7% recorded at 
Swiss asylum seeker reception centres [42]. MRSA car-
riage also proved more prevalent in the study popula-
tion than among regular travellers hospitalised in the 
(sub)tropics: Khawaja et al. reported 6.6% (25/377) for 
2010–2013 [39], Kaspar et al. 2% for 2012–2013 [43], 
Nemeth et al. 1.2% for 2009–2011 [44], and Birgand 
et al. 3.8% for 2012–2013 [45]. This relevant and valu-
able finding should be taken heed of when drawing up 
infection control guidelines for hospital admission of 
refugees and asylum seekers.
An analysis of spa-types revealed that the MRSA strains 
differ from those most commonly seen in clinical sam-
ples in Finland (t008, t172, t067) [46]. Clear differences 
were found between those with different countries of 
origin, suggesting that the strains had not originated 
in Finland but that refugees had been MRSA carriers 
on arrival. The median time from arrival in Finland to 
first sample was almost twice as long among MRSA 
carriers than among non-carriers. A tendency was seen 
for MRSA rates to grow as their stay in Finland length-




The results of univariate and multivariable risk factor analyses of meticillin-resistant Staphylococcus aureus colonisation 













OR (95% Cl) 
in univariate 
analysis
p value in 
univariate 
analysis
AOR (95% CI) 
in multivariable 
analysisa
p value in 
multivariable 
analysis
n n % n %
Sex
Female 237 47 19.8 190 80.2 1.0 NA NA NA
Male 210 48 22.9 162 77.1 1.2 (0.8–1.9) 0.435 NA NA
Age group (years) 0.806
0–5 54 13 24.1 41 75.9 1.0 NA NA NA
6–15 53 11 20.8 42 79.2 0.8 (0.3–2.1)b 0.681 NA NA
16–25 121 22 18.2 99 81.8 0.7 (0.3–2.1)b 0.369 NA NA
26–35 152 36 23.7 116 76.3 1.0 (0.5–2.0)b 0.954 NA NA
> 35 67 13 19.4 54 80.6 0.8 (0.3–1.8)b 0.535 NA NA
Geographical regionc 0.002
Europe 26 2 7.7 24 92.3 1.0 NA 1.0 NA
North Africa and Middle 
East 268 75 27.6 197 72.4 4.7 (1.1–20.2)
d 0.040 4.5 (1.0–19.7)d 0.044
Sub-Saharan Africa 86 11 13.4 71 86.6 1.8 (0.4–8.5)d 0.482 1.7 (0.4–8.4)d 0.500
Asia 57 5 8.8 52 91.2 1.2 (0.2–6.4)d 0.870 1.2 (0.2–6.4)d 0.864
Other or unknown 10 2 20.0 8 80.0 3.0 (0.4–24.9)d 0.309 3.2 (0.4–26.9)d 0.279
Prior hospitalisation abroad
No or not specified 367 72 19.6 295 80.4 1.0 NA NA NA
Yes 80 23 28.8 57 71.3 1.7 (1.0–2.9) 0.072 NA NA
Prior invasive procedure abroad
No or not specified 398 78 19.6 320 80.4 1.0 NA 1.0 NA
Yes 49 17 34.7 32 65.3 2.2 (1.2–4.1) 0.017 2.0 (1.1–3.9) 0.033
Prior ICU care abroad
No or not specified 429 89 20.7 340 79.3 1.0 NA NA NA
Yes 18 6 33.3 12 66.7 1.9 (0.7–5.2) 0.208 NA NA
Time from arrival to first 
sample (days, median)e 59 97 51 1.05 (0.99–1.10)
e 0.079 NA NA
Charlson comorbidity index (points) 0.626
0 417 93 22.3 324 77.7 1.0 NA NA NA
1 6 1 16.7 5 83.3 0.7 (0.1–6.0)f 0.743 NA NA
2–3 20 1 5.0 19 95.0 0.1 (0.02–1.4)f 0.100 NA NA
4–5 2 0 0 2 100 NA NA NA NA
> 5 2 0 0 2 100 NA NA NA NA
AOR: adjusted odds ratio; CI: confidence interval; ICU: intensive care unit; MRSA: meticillin-resistant Staphylococcus aureus; NA: not 
applicable; OR: odds ratio; SD: standard deviation.
aWhen selecting the variables for the multivariable model with binary logistic regression, the Akaike information criteria (AIC) was used. Time 
between arrival and first sample was not known for all cases; missing values were taken into account by multiple imputations, assuming 
that data were missing at random.
bCompared with the youngest age group.
cPatients’ countries of origin in the various geographical regions:
Europe: Albania, Georgia, Greece, Kosovo*, Russia, Serbia, Ukraine;
North Africa and Middle East: Iraq, Iran, Jordan, Kuwait, Lebanon, Morocco, Syria, Turkey, Yemen;
Sub-Saharan Africa: Burundi, Cameroon, Congo, Ethiopia, Eritrea, Gambia, Ghana, Kenya, Nigeria, Rwanda, Somalia, South Africa, Sudan, 
Uganda, Zambia;
Asia: Afghanistan, Azerbaijan, Kazakhstan, China, Kyrgyzstan, Myanmar, Nepal, Pakistan, Sri Lanka.
dCompared with Europe.
en = 283, only in 283/447 cases arrival date to Finland was known. Analysed as a continuous variable, OR and adjusted OR given per 30 days.
fCompared with those with 0 points.
*This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the 
International Court of Justice Opinion on the Kosovo Declaration of Independence.
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Colonisation by multiresistant bacteria
The rising number of CPEs has aroused great concern 
in Europe [47]. CPE findings have been reported for 
0–2.1% of refugee patients [37,41,48]. Likewise, our 
study found the CPE rates to be low. Of course, even 
at these levels, they exceed the background rate in 
Finland [49]; special attention is warranted, since they 
may rise further, running parallel to increasing AMR 
prevalence in the various countries of origin.
As for MRAB and MRPA colonisation, two cases of each 
were identified; none with VRE were found, a valuable 
piece of information for professionals planning infec-
tion control measures in hospitals.
ESBL-PE were the most commonly recorded MDR bac-
teria. Detected among one third of the refugees and 
migrants, the rates remained lower than in two studies 
by Reinheimer et al. [37,38] in Germany, reporting 52.1% 
(61/117) and 58.7% (84/143) prevalence, yet accorded 
with rates identified in samples from unaccompanied 
refugee minors in Frankfurt in 2015 (35.3%, 42/119) 
[50]. The colonisation rates among refugees resembled 
those reported for regular travellers (20–70%) [51,52], 
the figures probably reflecting country-related back-
ground colonisation rates. Traveller studies show sig-
nificant differences depending on destination [51,52]; 
the highest numbers are seen among visitors to major 
risk regions such as the Indian subcontinent.
It appears, however, that the initial ESBL-PE rates of 
asylum seekers and refugees on arrival in Finland may 
actually have been higher than recorded here: those 
with longer time since arrival had a lower ESBL-PE car-
riage frequency than those sampled soon after immi-
gration. Indeed, recent follow-up studies show that 
travellers’ ESBL-PE carriage tends to be transient and 
detectable only for a few months after return [15,53]. 
While the acquisition rates reported in traveller stud-
ies are based on samples collected soon after travel-
lers’ return, in the present study the median time from 
arrival to sampling was approximately 8 weeks. Further 
research is needed into carriage duration among refu-
gees and migrants or other people with a recent history 
of long-term exposure to MDR bacteria.
A substantial proportion of our ESBL-PE isolates 
proved co-resistant to levofloxacin, tobramycin or co-
trimoxazole, which accords with the results of stud-
ies exploring colonisation among travellers [4,9,11,12]. 
Co-resistance to levofloxacin correlated with resistance 
to tobramycin but not co-trimoxazole. This finding may 
be related to a genetic linkage between the resistance 
mechanisms of the first two [54,55].
Risk factor analysis
To identify potential risk factors of MRSA and ESBL-PE 
colonisation, we conducted univariate and multivari-
able analysis of the items derived from the patient 
records. To our knowledge, until now, risk factor 
analyses have not been included in refugee/migrant 
studies [36-38,41,48,50].
As independent risk factors of MRSA colonisation, we 
recognised geographical region and prior invasive pro-
cedure outside the Nordic countries. The latter accords 
with previous studies showing prior healthcare con-
tact to be a risk factor of MRSA colonisation at hospi-
tal admission [56,57]. In our research, the highest risk 
of MRSA colonisation was seen among patients from 
North Africa and Middle East, which is in line with an 
investigation by Stenhem et al. analysing imported 
MRSA cases in Sweden from 2000 to 2003 [58]. Some 
of the other risk factors of MRSA colonisation such as 
prior infections or antibiotic treatments, occupation 
(e.g. healthcare worker) or contact with livestock could 
not be covered, due to the retrospective nature of our 
study [57].
For ESBL-PE colonisation, the final multivariable analy-
ses revealed as independent risk factors geographical 
region, young age (< 6 years old), short time from arrival 
to first sample, and prior hospitalisation outside the 
Nordic countries. Geographical region has been identi-
fied in virtually all traveller studies analysing ESBL-PE 
risk factors [5,12-14,16,52]. The highest risk has been 
linked with Asia and the Middle East [5-7,9-18], a find-
ing that agrees with our results. Likewise, prior hos-
pitalisation has been established as a risk factor for 
MDR bacterial carriage among travellers [59]. One 
previous result contradictory to ours showed a corre-
lation between young age and lower rates of ESBL-PE 
colonisation [13]. Indeed, refugee children and travel-
ling minors cannot be regarded as comparable: tourist 
children’s exposure to food/drink contaminated with 
intestinal microbes is of shorter duration, and, moreo-
ver, trying to avoid diarrhoea, their parents probably 
select less risky food for them.
Traveller studies have also identified a number of 
other risk factors, such as occurrence of diarrhoea 
[5,6,9,10,13-15] and use of antibiotics [6,13,15-17]. 
Unfortunately, these predisposing factors could not be 
included in our analyses since such data could not be 
consistently drawn from our patient records.
Limitations
Due to the retrospective design of our study, the data 
were limited to those available in patient records. Some 
relevant factors such as antibiotic use could not be 
analysed. Information concerning the itineraries of the 
refugees and asylum seekers was lacking, and dates of 
arrival in Finland were recorded for only 63.3% of the 
patients. The research was conducted in a tertiary hos-
pital which is reflected in the selection of the patients. 
Females were over-represented in our study population 
(53.0%), probably because of the large proportion of 
pregnancy-related hospital visits. After the beginning 
of 2015 only 21.2% of all asylum seekers arriving in 
Finland were female [60].
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Conclusions
Our study shows considerable carriage rates for MDR 
bacteria among refugees and asylum seekers admitted 
to a tertiary hospital in Finland. The data suggest that 
these patients should be considered a risk group that 
requires both screening of MDR bacteria and infection 
control measures at entry to hospitals in low-preva-
lence countries. In particular the refugee and migrant 
population’s considerable MRSA colonisation rate war-
rants attention in healthcare settings.
Note
*This designation is without prejudice to positions 
on status, and is in line with United Nations Security 
Council Resolution 1244/99 and the International 
Court of Justice Opinion on the Kosovo Declaration of 
Independence.
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